Galidesivir

Galidesivir

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
CAS Number	249503-25-1 Y HCl: 222631-44-9 Y
PubChem CID	69211190
ChemSpider	8620968
UNII	OLF97F86A7 HCl: 1EL1K52SH1 Y
Chemical and physical data
Formula	C11H15N5O3
Molar mass	265.268 g·mol−1
3D model (JSmol)	Interactive image
SMILES O[C@H]3[C@H](c2c1ncnc(N)c1[nH]c2)N[C@H](CO)[C@H]3O
InChI InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1 Key:AMFDITJFBUXZQN-KUBHLMPHSA-N

Galidesivir (BCX4430, immucillin-A) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease, as well as Zika virus. Currently, galidesivir is under phase 1 human trial in Brazil for coronavirus.

It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, flaviviruses, and phleboviruses. Galidesivir has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection, and development for use in humans was then being fast-tracked due to concerns about the lack of treatment options for the 2013-2016 Ebola virus epidemic in West Africa.

Galidesivir later showed efficacy against Zika virus in a mouse model.

Galidesivir abrogates viremia in Zika virus–infected rhesus Macaques.

Galidesivir is one of several antiviral drugs being tested for coronavirus disease 2019.

On April 9, 2020, BioCryst opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19.

See also